Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene

Molecular Biotechnology

Volumn 58, Issue 1, 2016, Pages 30-36

  Rashnonejad, Afrooz ^a,b   Chermahini, Gholamhossein Amini ^a   Li, Shaoyong ^c   Ozkinay, Ferda ^a   Gao, Guangping ^c  

^a EGE UNIVERSITY   (Turkey)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated viral vector; Electron microscopy; Gene therapy; Human embryonic kidney 293 cells; Spinal muscular atrophy (SMA); Survival Motor Neuron (SMN) gene; Transient transfection

Indexed keywords

BRAIN; CELLS; CLONING; CYTOLOGY; ELECTRON MICROSCOPES; ELECTRON MICROSCOPY; GENE EXPRESSION; GENES; MOLECULAR BIOLOGY; NEURONS; QUALITY CONTROL; VECTORS;

HUMAN EMBRYONIC KIDNEY 293 CELLS; SPINAL MUSCULAR ATROPHY; SURVIVAL MOTOR NEURONS; TRANSIENT TRANSFECTION; VIRAL VECTORS;

GENE THERAPY;

ADENO ASSOCIATED VIRAL VECTOR SEROTYPE 9; ADENOVIRUS VECTOR; BETA ACTIN; COMPLEMENTARY DNA; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; SURVIVAL MOTOR NEURON PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ELECTRON MICROSCOPY; ENHANCER REGION; GENE EXPRESSION; GENE MAPPING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; LARGE SCALE PRODUCTION; PLASMID; POLYADENYLATION; PROMOTER REGION; PROTEIN EXPRESSION; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILENT MUTATION; SILVER STAINING; TRANSIENT TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; REGULATORY SEQUENCE;

DEPENDOVIRUS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; PROMOTER REGIONS, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; SMN COMPLEX PROTEINS; TRANSFECTION;

EID: 84954376750     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-015-9899-5     Document Type: Article

References (15)

1. Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002). Quantitative analyses of smn1 and smn2 based on real-time lightcycler pcr: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. The American Journal of Human Genetics,70, 358–368.
2. Rossoll, W., & Bassell, G. J. (2009). Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results and Problems in Cell Differentiation,48, 289–326.
3. D’Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011). Spinal muscular atrophy. Orphanet Journal of Rare Diseases,6, 1–10.
4. Mulcahy, P. J., Iremonger, K., Karyka, E., Herranz-Martín, S., Shum, K. T., Tam, J. K., et al. (2014). Gene therapy: a promising approach to treating spinal muscular atrophy. Human Gene Therapy,25, 575–586.
5. Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology,28, 271–274.
6. Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Human Molecular Genetics,20, 681–693.
7. Benkhelifa-Ziyyat, S., Besse, A., Roda, M., Duque, S., Astord, S., Carcenac, R., et al. (2013). Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Molecular Therapy,21, 282–290.
8. Passini, M. A., Bu, J., Richards, A. M., Treleaven, C. M., Sullivan, J. A., O’Riordan, C. R., et al. (2014). Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Human Gene Therapy,25, 619–630.
9. Gao, G. P., Zhong, L., & Danos, O. (2011). Exploiting natural diversity of AAV for the design of vectors with novel properties. Methods in Molecular Biology,807, 93–118.
10. Gao, G. P., & Sena-Esteves, M. (2012). introducing genes into mammalian cells: Viral vectors. In M. R. Green & J. Sambrook (Eds.), Molecular cloning: A laboratory manual (Vol. 2, pp. 1209–1313). New York: Cold Spring Harbor Laboratory Press.
11. Vannucci, L., Lai, M., Chiuppesi, F., & Pistello, M. (2013). Viral vectors: a look back and ahead on gene transfer technology. New Microbiologica,36, 1–22.
12. Grieger, J. C., & Samulski, R. J. (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods in Enzymology,507, 229–254.
13. Miao, C. H., Ohashi, K., Patijn, G. A., Meuse, L., Ye, X., Thompson, A. R., et al. (2000). Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Molecular Therapy,1, 522–532.
14. Ehrhardt, A., & Kay, M. A. (2002). A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood,99, 3923–3930.
15. Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., et al. (2010). Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Human Gene Therapy,21, 1259–1271.